Form S-1/A
STEREOTAXIS, INC. filed this Form S-1/A on 07/01/2004
Document Outline
Entire Document (1785.6 KB)
Subdocument 1 - S-1/A - AMENDMENT TO REGISTRATION STATEMENT
Page 1 - As filed with the Securities and Exchange Commission on July 1, 2004
Page 2 - See Risk Factors on page 7 to read about factors you should consider before buying shares of the com
Page 3 - N/A
Page 4 - PROSPECTUS SUMMARY
Page 5 - N/A
Page 6 - Our Strategy
Page 7 - THE OFFERING
Page 8 - SUMMARY FINANCIAL DATA
Page 9 - N/A
Page 10 - RISK FACTORS
Page 11 - You may have difficulty evaluating our business and operating results because we are still in the ea
Page 12 - We may lose or fail to attract physician thought leaders .
Page 13 - We will likely experience long and variable sales cycles, which could result in substantial fluctuat
Page 14 - We may not generate cash from operations necessary to commercialize our existing products and invest
Page 15 - Risks associated with international manufacturing and trade could negatively impact the availability
Page 16 - We may be unable to protect our technology from use by third parties.
Page 17 - Third parties may assert that we are infringing their intellectual property rights.
Page 18 - We may be subject to damages resulting from claims that our employees or we have wrongfully used or
Page 19 - We may fail to comply with continuing regulatory requirements of the FDA and other authorities and b
Page 20 - Our suppliers or we may fail to comply with the FDA quality system regulation.
Page 21 - The application of state certificate of need regulations and compliance with federal and state licen
Page 22 - We may lose our key personnel or fail to attract and retain additional personnel.
Page 23 - Risks Related To Our Common Stock
Page 24 - Sales of a substantial number of shares of our common stock in the public market after this offering
Page 25 - Evolving regulation of corporate governance and public disclosure may result in additional expenses
Page 26 - Our common stock has not been publicly traded, and we expect that the price of our common stock will
Page 27 - You should read this prospectus completely and with the understanding that our actual results may be
Page 28 - USE OF PROCEEDS
Page 29 - CAPITALIZATION
Page 30 - DILUTION
Page 31 - N/A
Page 32 - SELECTED FINANCIAL DATA
Page 33 - N/A
Page 34 - MANAGEMENT S DISCUSSION AND ANALYSIS
Page 35 - N/A
Page 36 - Critical Accounting Policies
Page 37 - Revenue Arrangements with Multiple Deliverables
Page 38 - Accounting for Income Taxes
Page 39 - Cost of Revenues.
Page 40 - Stock-based Compensation Expense.
Page 41 - Cost of Revenues.
Page 42 - Stock-based Compensation Expense.
Page 43 - Net cash used in operating activities.
Page 44 - N/A
Page 45 - N/A
Page 46 - N/A
Page 47 - Recent Accounting Pronouncements
Page 48 - Quantitative and Qualitative Disclosures About Market Risk
Page 49 - BUSINESS
Page 50 - N/A
Page 51 - Background
Page 52 - N/A
Page 53 - The Stereotaxis Value Proposition
Page 54 - N/A
Page 55 - Business Strategy
Page 56 - Overview of the Stereotaxis System
Page 57 - CARDIODRIVE Automated Catheter Advancer.
Page 58 - Clinical Applications
Page 59 - N/A
Page 60 - N/A
Page 61 - Collaborations
Page 62 - Philips Alliance.
Page 63 - Research and Development
Page 64 - Manufacturing
Page 65 - Sales and Marketing
Page 66 - Step Two: Recurring sales of disposable interventional devices, software and service.
Page 67 - N/A
Page 68 - University of Virginia.
Page 69 - Government Regulation
Page 70 - N/A
Page 71 - N/A
Page 72 - N/A
Page 73 - Insurance
Page 74 - Litigation
Page 75 - SCIENTIFIC ADVISORY BOARD
Page 76 - N/A
Page 77 - MANAGEMENT
Page 78 - Douglas M. Bruce
Page 79 - Gregory R. Johnson, Ph.D.,
Page 80 - David J. Parker
Page 81 - Compensation Committee Interlocks and Insider Participation
Page 82 - Executive Compensation
Page 83 - Stock Option Grants in 2003
Page 84 - Limitation of Liability and Indemnification
Page 85 - Agreements with Named Executive Officers
Page 86 - N/A
Page 87 - Termination of Employment Agreement with Former Chief Financial Officer
Page 88 - N/A
Page 89 - N/A
Page 90 - N/A
Page 91 - N/A
Page 92 - CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
Page 93 - N/A
Page 94 - Relationship with Siemens
Page 95 - Relationship with J J
Page 96 - Indemnification and Employment Agreements
Page 97 - Other Transactions
Page 98 - PRINCIPAL STOCKHOLDERS
Page 99 - N/A
Page 100 - N/A
Page 101 - N/A
Page 102 - N/A
Page 103 - DESCRIPTION OF CAPITAL STOCK
Page 104 - Warrants
Page 105 - Anti-Takeover Provisions of Delaware Law and Charter Provisions
Page 106 - N/A
Page 107 - Nasdaq National Market Listing
Page 108 - SHARES ELIGIBLE FOR FUTURE SALE
Page 109 - N/A
Page 110 - CERTAIN MATERIAL U.S. FEDERAL TAX CONSEQUENCES TO NON-U.S. HOLDERS
Page 111 - Dispositions of Common Stock.
Page 112 - Backup Withholding.
Page 113 - UNDERWRITING
Page 114 - N/A
Page 115 - N/A
Page 116 - VALIDITY OF SECURITIES
Page 117 - STEREOTAXIS, INC.
Page 118 - Report of Independent Registered Public Accounting Firm
Page 119 - STEREOTAXIS, INC.
Page 120 - STEREOTAXIS, INC.
Page 121 - STEREOTAXIS, INC.
Page 122 - STEREOTAXIS, INC.
Page 123 - STEREOTAXIS, INC.
Page 124 - STEREOTAXIS, INC.
Page 125 - STEREOTAXIS, INC.
Page 126 - STEREOTAXIS, INC.
Page 127 - STEREOTAXIS, INC.
Page 128 - STEREOTAXIS, INC.
Page 129 - STEREOTAXIS, INC.
Page 130 - STEREOTAXIS, INC.
Page 131 - STEREOTAXIS, INC.
Page 132 - STEREOTAXIS, INC.
Page 133 - STEREOTAXIS, INC.
Page 134 - STEREOTAXIS, INC.
Page 135 - STEREOTAXIS, INC.
Page 136 - STEREOTAXIS, INC.
Page 137 - STEREOTAXIS, INC.
Page 138 - STEREOTAXIS, INC.
Page 139 - STEREOTAXIS, INC.
Page 140 - STEREOTAXIS, INC.
Page 141 - STEREOTAXIS, INC.
Page 142 - STEREOTAXIS, INC.
Page 143 - Part II
Page 144 - N/A
Page 145 - N/A
Page 146 - N/A
Page 147 - N/A
Page 148 - Stereotaxis, Inc.
Page 149 - N/A
Page 150 - N/A
Page 151 - SIGNATURES
Page 152 - N/A
Page 153 - EXHIBIT INDEX
Page 154 - N/A
Page 155 - N/A
Subdocument 2 - EX-23.1 - CONSENT OF ERNST & YOUNG LLP
Page 1 - N/A
© Copyright Stereotaxis 2015